ROCKVILLE, Md. – May 8, 2026
AAVnerGene Inc. announced the launch of AAVone®2.1, the next-generation evolution of its proprietary single-plasmid AAV production platform, designed to significantly improve the manufacturing efficiency, scalability and quality of AAV-based gene therapies. The company reported that the upgraded platform achieved approximately 1×10¹⁶ genome copies (GC)/L of cell culture along with more than 70% full capsids at harvest, positioning the technology as a major advancement in adeno-associated virus (AAV) vector production for the rapidly growing gene therapy industry.
The announcement highlights increasing industry focus on overcoming manufacturing bottlenecks limiting commercialization of gene therapies. AAV vector production remains one of the most technically complex and expensive processes in advanced biologics manufacturing, with productivity limitations, empty capsid formation and purification inefficiencies continuing to challenge large-scale clinical and commercial deployment. AAVnerGene stated that AAVone®2.1 was specifically engineered to address these manufacturing constraints while supporting more cost-effective and scalable production workflows.
AAVone®2.1 Targets Higher Yield and Better Vector Quality
According to the company, AAVone®2.1 represents a significant improvement over both the original AAVone®1.0 platform and conventional multi-plasmid AAV production systems, which often generate large proportions of empty viral capsids during manufacturing. Empty capsids can complicate purification processes, increase manufacturing costs and potentially affect therapeutic performance, making high full-capsid ratios a major objective for gene therapy developers.
The upgraded single-plasmid platform demonstrated strong performance across multiple AAV serotypes and compatibility with standard HEK293-based manufacturing workflows, allowing integration into existing production infrastructure. AAVnerGene stated that the platform may reduce plasmid requirements, lower purification burdens, minimize processing steps and shorten overall manufacturing timelines while improving vector quality and scalability.
Advertisement
Dr. Qizhao Wang, Chief Technology Officer of AAVnerGene, noted that traditional multi-plasmid systems have supported the gene therapy industry for decades but continue facing major limitations in productivity and manufacturing complexity. He explained that AAVone®2.1 was developed as a simplified production approach capable of improving vector yield and full-capsid ratios while reducing operational challenges associated with conventional AAV manufacturing systems.
Gene Therapy Manufacturing Challenges Drive Innovation
The global gene therapy sector has experienced rapid growth in recent years as companies pursue treatments for rare genetic disorders, neurological diseases, inherited blindness and oncology applications. However, scalable manufacturing of high-quality viral vectors remains one of the largest barriers preventing broader commercialization and cost-effective patient access.
Industry analysts continue identifying AAV manufacturing efficiency as a critical determinant of gene therapy development timelines, production costs and long-term commercial viability. Conventional production systems often require multiple plasmids and extensive purification procedures, creating operational complexity and increasing manufacturing expenses. Technologies capable of improving vector productivity while reducing empty capsid formation are therefore attracting significant attention across the biotechnology sector.
AAVnerGene Chief Executive Officer Daozhan Yu, PhD, stated that manufacturing cost, vector quality and process scalability remain among the most important commercial challenges facing AAV gene therapy programs globally. He said the company believes AAVone®2.1 has the potential to simplify manufacturing workflows while helping more gene therapy programs become clinically and commercially viable.
Platform Expansion Supports Future Gene Therapy Growth
AAVnerGene confirmed that multiple partners have already licensed the AAVone® platform to support development of gene therapy programs. Beyond manufacturing technology, the company continues expanding additional platforms including AAV-Q, a potency and rcAAV assay system, and ATHENA, a capsid engineering platform designed to optimize viral vector performance, efficiency and safety.
The launch of AAVone®2.1 reflects broader industry efforts to modernize viral vector production as demand for gene therapy manufacturing capacity accelerates worldwide. As more gene therapies move toward commercial approval, scalable and cost-efficient production technologies are expected to play a critical role in expanding patient access and supporting next-generation biologic innovation.
Source: AAVnerGene press release
